Jun 26 |
Silo Pharma Partners with AmplifyBio to Advance SPC-15 for PTSD and Anxiety
|
Jun 7 |
Silo Pharma Announces Successful Production of its SP-26 Ketamine Implant for Fibromyalgia
|
Jun 6 |
Silo Pharma Announces Closing of $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
|
Jun 5 |
Crude Oil Rises 1%; Dollar Tree Shares Fall After Q1 Results
|
Jun 5 |
Silo Pharma announces $2 million registered direct offering
|
Jun 5 |
Silo Pharma Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
|
Jun 4 |
Silo Pharma Submits Pre-Investigational New Drug Application to FDA for SPC-15 as a Treatment for PTSD and Anxiety
|
May 21 |
Silo Pharma Announces Positive Results from Study for Depression Treatment, Remission, and Relapse Prevention
|
May 14 |
Silo Pharma to Participate in FDA Meeting Exploring Emerging Therapeutic Interest in Ketamine
|
Apr 23 |
Silo Pharma Announces Positive Results for Intranasal PTSD Treatment
|